BioWorld

Nov. 18, 2002

Stock Winners and Losers For The Week

Clinical Trial Update: October 2002

Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: October 2002

FDA Submissions, Approvals And Other Actions: October 2002

BioWorld Stock Report For Public Biotechnology Companies

Cash-Positive Companies Have Best Chance Of Impressing VCs

Walk into any funding firm and you will see mountains of papers summarizing this company's dream and that company's vision. (BioWorld Financial Watch) Read More

Money Raised Year To Date

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...